Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion

News Conference News VIVA 2023

‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion

November 03, 2023

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

AHA, Editors, and Cardiologists Ask: How Did ‘Racist’ Paper Made It to Print?

News Conference News

AHA, Editors, and Cardiologists Ask: How Did ‘Racist’ Paper Make It to Print?

Michael O'Riordan

August 05, 2020

Dedicated Structural Heart Training Pathway in the Works for Surgeons

News Conference News STS 2020

Dedicated Structural Heart Training Pathway in the Works for Surgeons

Yael L. Maxwell

February 04, 2020

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

May 16, 2019

3-D Printing Opportunities Emerge for Cardiologists, Hospitals, and Device Companies Alike

News Conference News TCT 2017

3-D Printing Opportunities Emerge for Cardiologists, Hospitals, and Device Companies Alike

Yael L. Maxwell

October 31, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

May 12, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.